 |
| |
|
Marina del Rey, CA - September 2, 2016
- SWI today announced that it has added three new and exiting companies to its QuickPicks list. Two of the recommendations, SunOpta and Origin Agritech are promising agricultural Biotech companies involved in the research, production and sale of organic products world-wide and in crop seed breeding and genetic improvement activities in the Peoples Republic of China respectively.
Corbus Pharmaceuticals is developing
a first in class, synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation and halts fibrotic processes. It is currently being evaluated in four Phase 2 clinical trials
.
We believe that these companies address
fast growing different segments of a world-wide market and are poised for significant growth. All three have strong average analyst "BUY" recommendations.
|
|
|
Average Analyst recommendation
"Buy" with a target of $7.09
|
|
|
S
unOpta Inc. (STKL) sources non-genetically modified (non-GMO) and organic ingredients; and manufactures and sells healthy food and beverage products in the United States, Canada, Europe, China, and Ethiopia.
|
|
|
|
|
Average Analyst recommendation
"Buy" with a target of $5.00
|
|
|
Quarterly Revenue Growth of 12.1%
|
|
Origin Agritech Limited (SEDD), an agricultural biotechnology company, engages in crop seed breeding and genetic improvement activities in the Peoples Republic of China. The company is involved in the research and development, production, sale, and marketing of crop seeds; and provision of related technical services. The company distributes its products to farmers through distributors and retailers.
|
|
|
|
|
Average Analyst recommendation
"Buy" with a target of $6.33
|
|
|
Breakthrough Therapies for Rare Inflammatory Diseases
|
|
Corbus's (CRBP) Resunab is a first in class, synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation and halts fibrotic processes. It is currently being evaluated in four Phase 2 clinical trials
|
|
|
|
|
Rainer Poertner - Chief Analyst
|
|
|
S
tockWatchIndex and SWI Research (SWI) are not registered investment advisers and the information provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has not been compensated for the publication of the information herein, does not own any stocks mentioned in this publication, but may consider acquiring positions for the SWI Portfolio in the future
. The included information is subject to change without notice. Please visit
www.swiresearch.com/#!legal-ease/lmvw1
for a full text of our Disclaimer, Privacy policy and Terms of Use.
|
|
|
|
|
|
|
|
